Volume 25, Number 9—September 2019
Genetic Characterization and Enhanced Surveillance of Ceftriaxone-Resistant Neisseria gonorrhoeae Strain, Alberta, Canada, 2018
|Antimicrobial drug||Etest MIC, μg/mL||Agar dilution, μg/mL||Interpretation||Genetic markers/mutations identified in genome: result|
||penA: mosaic 60.001, A311V, T483S; mtrR promoter: –35A deletion; mtrR: wild types for A39 and G45; porB: G120K, A121D; porB structure: porB1b; ponA: L421P
||23S rRNA A2059G and C2611T: absent; ermB: negative; ermC: negative; mtrR promoter: –35A deletion; mtrR: wild types for A39 and G45
||gyrA: S91F and D95A; parC: D86, S87R, and wild type S88
||rpsJ: rpsJ_3 (V57M); tetM: negative; mtrR promoter: –35A deletion; mtrR: wild types for A39 and G45
||Genetic resistance determinants not determined
*Interpretations based on agar dilution. NA, breakpoint not available; ND, not done; NS, nonsusceptible; R, resistant; S, susceptible.
†Tetracycline resistance would be intermediate on the basis of Etest MIC.
Page created: August 21, 2019
Page updated: August 21, 2019
Page reviewed: August 21, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.